Clinical features, effectiveness of therapy and quality of life of patients with type 2 diabetes and comorbid schizophrenia

Abstract

IntroductionAccording to previous studies, about 8,8-14,5% cases of schizophrenia is comorbid to type 2 diabetes. The focus of the study was the evaluation and dynamics of positive and negative symptoms in case of combination of the diseases.Objectives100 patients were divided in two groups: 48 patients was assigned to receive a monotherapy treatment with antipsychotic; 52 patients received the combination of antipsychotics, nootropics and antioxidants. The efficiency criterion was the dynamics of the questionnaire The quality of life of patients SF- 36, Hamilton’s scale of Depression and anxiety, overall score on a scale for evaluation positive and negative symptoms (PANSS).MethodsAfter treatment the physical component of health is 41,38% in the first group and 56,34% in the second group (p≤ 0,05). The psychical component of health is 39,79% in the first group and 50,8% in the second group (p≤ 0,05). Also statistically confirmed (p≤ 0,05) in the patients of the second group the improvement on the Hamilton’s scale of Depression and anxiety questionnaire and PANSS.ResultsAfter treatment the physical component of health is 41,38% in the first group and 56,34% in the second group (p≤ 0,05). The psychical component of health is 39,79% in the first group and 50,8% in the second group (p≤ 0,05). Also statistically confirmed (p≤ 0,05) in the patients of the second group the improvement on the Hamilton’s scale of Depression and anxiety questionnaire and PANSS.ConclusionsAccording to Quality of Life questionnaire combination of antipsychotic, nootropic, antioxidant is significant more effective than treatment only with antipsychotic.